Status:
COMPLETED
Measurement of Plasma and Intracellular Concentrations of Raltegravir
Lead Sponsor:
University of Nebraska
Conditions:
HIV
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performan...
Detailed Description
Integrase strand transfer inhibitors are one of the newest class of antiretroviral drugs. This class of drugs inhibit the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for vi...
Eligibility Criteria
Inclusion
- Be of age greater than or equal to 19 years
- Have documented HIV
- Be taking RAL for at least 7 days
Exclusion
- Any acute intercurrent illness that might interfere with the interpretation of the study
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01214486
Start Date
October 1 2010
End Date
June 30 2011
Last Update
August 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198